<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559178</url>
  </required_header>
  <id_info>
    <org_study_id>P2020/338 / B4062020000092</org_study_id>
    <nct_id>NCT04559178</nct_id>
  </id_info>
  <brief_title>Fluid Challenges and Microcirculation</brief_title>
  <acronym>FC</acronym>
  <official_title>Impact of Intraoperative Fluid Challenges Administration on Macro and Microcirculation in Patients Undergoing High-risk Abdominal Surgery and Situated in the Gray Zone of Pulse Pressure Variation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective observational study is to assess the impact of fluid challenge&#xD;
      administration on macro and microcirculation in patients situated in the gray zone during a&#xD;
      high risk abdominal surgery&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fluid optimization is a key goal in anesthesia. It allows to titrate fluid bolus based on&#xD;
      flow variables or dynamic parameters of fluid responsiveness (pulse pressure variation (PPV)&#xD;
      or stroke volume variation (SVV)).&#xD;
&#xD;
      When PPV or SVV is above 13%, the patient will usually respond to a bolus of fluid while when&#xD;
      PPV or SVV is below 9%, the patient will normally not respond to it. Between 9% and 13%, it&#xD;
      is a gray zone where the effect of a fluid bolus is uncertain.&#xD;
&#xD;
      The overall goal of fluid bolus administration is of course to optimize macrocirculation&#xD;
      (stroke volume and cardiac output) but also (and probably more importantly) end organ tissue&#xD;
      perfusion. However, regional tissue perfusion is not widely monitored during surgery.&#xD;
      However, we do have some monitoring tools to assess microcirculation at the bedside.&#xD;
&#xD;
      Investigation of microcirculation in addition to macro circulation may allow clinicians to&#xD;
      know if a patient situated in the gray zone may or not increase microcirculation variables&#xD;
      while macrocirculation variables are well known to be of little value to predict fluid&#xD;
      responsiveness.&#xD;
&#xD;
      The goal of this study is to assess microcirculation variables in patients situated in the&#xD;
      gray zone (PPV between 9%-13%), and to assess macro and microcirculation responses to a&#xD;
      standardized fluid challenge of 4 ml/kg of a balanced crystalloid solution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 25, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microvascular flow index</measure>
    <time_frame>day 0</time_frame>
    <description>Comparison of this index before and after the fluid challenge</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Surgery</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluid challenge</intervention_name>
    <description>fluid challenge administration when patient is in the gray zone</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for a high-risk abdominal surgery and equipped with a minimally&#xD;
        uncalibrated pulse contour analysis monitoring device as part of their anesthetic care.&#xD;
&#xD;
        All patients will have the hemodynamic monintoring to assess macrocirculation and&#xD;
        sublingual microcirculation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing a high-risk abdominal surgery&#xD;
&#xD;
          -  Patients equipped with a minimally invasive cardiac output monitoring device in order&#xD;
             to optimize fluid administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Ejection fraction &lt;40%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alexandre JOOSTEN, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandra Colesnicenco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ERASME</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Joosten, MD PhD</last_name>
    <phone>+33648600103</phone>
    <email>joosten-alexandre@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Colesnicenco, MD</last_name>
    <phone>+3225553111</phone>
    <email>alexandra.colesnicenco@erasme.ulb.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bicetre hospital</name>
      <address>
        <city>Le Kremlin-BicÃªtre</city>
        <state>Val De Marne</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasme University Hospital</investigator_affiliation>
    <investigator_full_name>Alexandre Joosten, MD PhD</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

